Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

498 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment Modification in Young Breast Cancer Patients.
Scharl A, Salterberg A, Untch M, Liedtke C, Stickeler E, Papathemelis T. Scharl A, et al. Among authors: untch m. Oncol Res Treat. 2016;39(3):122-8. doi: 10.1159/000444355. Epub 2016 Feb 24. Oncol Res Treat. 2016. PMID: 27031253 Review.
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Loibl S, O'Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, Huober J, Golshan M, von Minckwitz G, Maag D, Sullivan D, Wolmark N, McIntyre K, Ponce Lorenzo JJ, Metzger Filho O, Rastogi P, Symmans WF, Liu X, Geyer CE Jr. Loibl S, et al. Among authors: untch m. Lancet Oncol. 2018 Apr;19(4):497-509. doi: 10.1016/S1470-2045(18)30111-6. Epub 2018 Feb 28. Lancet Oncol. 2018. PMID: 29501363 Clinical Trial.
Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis.
Fasching PA, Hartkopf AD, Gass P, Häberle L, Akpolat-Basci L, Hein A, Volz B, Taran FA, Nabieva N, Pott B, Overkamp F, Einarson H, Hadji P, Tesch H, Ettl J, Lüftner D, Wallwiener M, Müller V, Janni W, Fehm TN, Schneeweiss A, Untch M, Pott D, Lux MP, Geyer T, Liedtke C, Seeger H, Wetzig S, Hartmann A, Schulz-Wendtland R, Belleville E, Wallwiener D, Beckmann MW, Brucker SY, Kolberg HC. Fasching PA, et al. Among authors: untch m. Breast Cancer Res Treat. 2019 Jan;173(2):319-328. doi: 10.1007/s10549-018-5008-3. Epub 2018 Oct 15. Breast Cancer Res Treat. 2019. PMID: 30324275
Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer: A Secondary Analysis of the GeparOcto Randomized Clinical Trial.
Pohl-Rescigno E, Hauke J, Loibl S, Möbus V, Denkert C, Fasching PA, Kayali M, Ernst C, Weber-Lassalle N, Hanusch C, Tesch H, Müller V, Altmüller J, Thiele H, Untch M, Lübbe K, Nürnberg P, Rhiem K, Furlanetto J, Lederer B, Jackisch C, Nekljudova V, Schmutzler RK, Schneeweiss A, Hahnen E. Pohl-Rescigno E, et al. Among authors: untch m. JAMA Oncol. 2020 May 1;6(5):744-748. doi: 10.1001/jamaoncol.2020.0007. JAMA Oncol. 2020. PMID: 32163106 Free PMC article. Clinical Trial.
Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge.
Jackisch C, Cortazar P, Geyer CE Jr, Gianni L, Gligorov J, Machackova Z, Perez EA, Schneeweiss A, Tolaney SM, Untch M, Wardley A, Piccart M. Jackisch C, et al. Among authors: untch m. Cancer Treat Rev. 2021 Sep;99:102229. doi: 10.1016/j.ctrv.2021.102229. Epub 2021 May 20. Cancer Treat Rev. 2021. PMID: 34139476 Free article. Review.
Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial.
Galactionova K, Loibl S, Salari P, Marmé F, Martin M, Untch M, Bonnefoi HR, Kim SB, Bear HD, McCarthy N, Gelmon KA, García-Sáenz JA, Kelly CM, Reimer T, Toi M, Rugo HS, Gnant M, Makris A, Burchardi N, Schwenkglenks M. Galactionova K, et al. Among authors: untch m. Front Oncol. 2022 Sep 5;12:886831. doi: 10.3389/fonc.2022.886831. eCollection 2022. Front Oncol. 2022. PMID: 36132153 Free PMC article.
Return of individual genomic research results within the PRAEGNANT multicenter registry study.
Huebner H, Ruebner M, Kurbacher C, Hadji P, Hartkopf AD, Lux MP, Huober J, Uhrig S, Taran FA, Overkamp F, Tesch H, Häberle L, Lüftner D, Wallwiener M, Müller V, Beckmann MW, Hein A, Belleville E, Untch M, Janni W, Fehm TN, Kolberg HC, Wallwiener D, Brucker SY, Schneeweiss A, Ettl J, Fasching PA, Michel LL. Huebner H, et al. Among authors: untch m. Breast Cancer Res Treat. 2023 Jan;197(2):355-368. doi: 10.1007/s10549-022-06795-x. Epub 2022 Nov 21. Breast Cancer Res Treat. 2023. PMID: 36409394 Free PMC article.
498 results